Cirius CEO Bob Baltera On Being In Hot Pursuit Of NASH
In a video interview at the Biotech Showcase, Cirius CEO Bob Baltera explains his company's approach to NASH and looks forward to milestones ahead for its insulin-sensitizing lead candidate MSDC-0602K.
You may also be interested in...
Privately held Cirius and NGM and big pharma Bristol-Myers Squibb are in Phase II for NASH with programs also working to validate non-invasive biomarkers for diagnosis, prognosis and treatment impact.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.